

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20201

IES OS JULIOTONIAS.

APPLICATION NUMBER

FILING RECEIPT DATE

FIRST NAMED APPLICANT.

AZTORNEY DOCKET NUMBER

09/871.974

06/04/2001

Mathew A. Von Wronski

2238-7

**CONFIRMATION NO. 6852** 

FORMALITIES LETTER

·2C00000006338905\*

NIXON & VANDERHYE P.C. 8th Floor 1100 North Glebe Road Arlington, VA 22201-4714

Date Mailed: 07/25/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- □ For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY



Serial No.: 09/87/974. Applicant: Uon WRONSKI Title: Novel Compounds For TARgetting	Atty: 9(25/0/ Client: 2238-7
Amendment	
Pages Specification	
Claims	•
Sheets Drawings: Formal	OF
Informal	(1)
Declaration (Pages)	/ 5
Assignment	1 2 2 200 B
Priority Document	1 SEP 1
Base Issue Fee Transmittal	2
Fee (Check)	HON TO TRADELIA
< hotherte Specificat	non sim
Other: Dadling Version of	specification / d
Other: Reduned Version of Letter PAgers Computer Readal	olecopus of Sequence 15T.

In re Patent Application o

Von Wronski et al.

Serial No. 09/871,974

Filed: June 4, 2001

Title:

COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS

0

CONTAINING THE SAME AND METHODS FOR THEIR USE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

#### RESPONSE/AMENDMENT/LETTER

ED STATES PATENT AND TRADEMAK

Atty Dkt. 2238 7 7 C#

Examiner: (Unassigned)

Date: October 25, 2001

Group Art Unit: 1653

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

minus highest number

### Fees are attached as calculated below: Total effective claims after amendment

	previously paid for $20$ (at least 20) = 0 x \$ 18.00	\$	0.00
	Independent claims after amendment $0$ minus highest number previously paid for $3$ (at least 3) = $0$ x \$ 84.00	\$	0.00
	If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
	Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$	0.00
	Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
	First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)  Please enter the previously unentered , filed	\$	0.00
	☐ Submission attached		
	Subtotal	\$	0.00
		\$ -\$	0.00
	If "small entity," then enter half (1/2) of subtotal and subtract	\$ -\$ \$	
	If "small entity," then enter half (1/2) of subtotal and subtract  Applicant claims "small entity" status.  Statement filed herewith	Ť	0.00
· · · · · · · · · · · · · · · · · · ·	If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith  Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

BJS:eaw

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

TOTAL FEE ENCLOSED \$

0.00

Signature:



Von Wronski et al.

Serial No.

09/871,974

Filed:

June 4, 2001

Atty. Ref.:

2238-7

Group:

1653

. . .

Examiner: (Unassigned)

For:

COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS,

COMPOSITIONS CONTAINING THE SAME AND

METHODS FOR THEIR USE

October 25, 2001

Assistant Commissioner for Patents Washington, DC 20231

Sir:

## **RESPONSE**

Responsive to the "Cover Letter for Resending Correspondence" dated October 12, 2001 (copy attached), the applicants respectfully submit that a response Notice to Comply dated July 25, 2001, was filed September 25, 2001, with the requisite items. A further copy of the applicants' response (i.e., Amendment) to the Notice to Comply dated July 25, 2001, is attached. A copy of the previously filed amended specification and marked-up specification are not being submitted herewith, to avoid confusion. A further copy of these documents could be submitted upon the Commissioner's further request. A copy of the undersigned's postcard receipt from the September 25, 2001, filing is also attached as evidence these papers were received in the Patent Office on September 25, 2001. Nothing further is believed to be required. The Office is requested to forward this application to an Examiner for prosecution on the merits.

## Von Wronski et al. Serial No. 09/871,974



Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

Ву:

**B. J. Sadoff** Reg. No. **36,663** 

BJS:eaw

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100





TECH CENTER 1600/2000

UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231

FILING DATE FIRST NAMED APPLICANT ATTY. DOCKET NO./TITLE

APPLICATION NUMBER 09/871,974

06/04/2001

Mathew A. Von Wronski

2238-7

CONFIRMATION NO. 6852

RESEND COVER LETTER

\*OC000000006893858\*

NIXON & VANDERHYE P.C. 8th Floor 1100 North Glebe Road Arlington, VA 22201-4714

Date Mailed: 10/12/2001

# **COVER LETTER FOR RESENDING CORRESPONDENCE**

A courtesy copy of the Notice mailed on 07/25/2001 is enclosed. The time period for reply continues to run from the mail date of that Notice.

A copy of this notice MUST be returned with the reply.